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Abstract
Background: The increasing prevalence of type 2 diabetes in the UK creates an additional,
potentially preventable burden on health care and service providers. The Healthier You: NHS
Diabetes Prevention Programme aims to reduce the incidence of type 2 diabetes through the
identification of people at risk and the provision of intensive lifestyle change support. The provision
of this care can be monitored through quality measurement at both the general practice and
specialist service level.
Aim: To develop quality measures through piloting to assess the validity, credibility, acceptability,
reliability, and feasibility of any proposed measures.
Design & setting: The non-experimental mixed design piloting study consists of consensus testing
and exploratory research with GPs, commissioners, and patients from Herefordshire, England.
Method: A mixed-method approach will be used to develop and validate measures for diabetes
prevention care and evaluate their performance over a 6-month pilot period consisting of
consensus testing using a modified RAND approach with GPs and commissioners; four focus
groups with 8–10 participants discussing experiences of non-diabetic hyperglycaemia (NDH),
perceived ability to access care and prevent diabetes, and views on potential quality measures; and
piloting final measures with at least five general practices for baseline and 6-month data.
Results: The findings will inform the implementation of the diabetes prevention quality measures
on a national scale while addressing any issue with validity, credibility, feasibility, and cost-
effectiveness.
Conclusion: Healthcare professionals and patients have the opportunity to evaluate the reliability,
acceptability, and validity of measures.
How this fits in
Relevant National Institute for Health and Social Care Excellence (NICE) guidelines and wider litera-
ture have identified potential measures to prevent patients identified with NDH progressing to dia-
betes or to help manage their condition. The application of these measures will be piloted with
clinicians, to identify their suitability.
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Introduction
The growing incidence and management of type 2 diabetes presents a significant cost to the NHS in
England.1 Type 2 diabetes is a preventable chronic disease, and lifestyle change can help reduce
risk.2
Patients with NDH have raised levels of Hb1Ac or fasting glucose but these are not high enough
to be diagnosed with type 2 diabetes.3 Intensive lifestyle modification programmes or interventions
can target people with NDH in order to delay or prevent the onset of type 2 diabetes and associ-
ated morbidity.4 The efficacy of lifestyle interventions requires further investigation, alongside evalu-
ation of diabetes incidence and risk reduction in health outcomes.5–8
As part of the Five Year Forward View, the NHS and Public Health England has announced the
development and implementation of a diabetes prevention programme to support people manag-
ing their own health.9 As part of this programme, interest has been expressed in developing quality
measures suitable for use at the general practice and clinical commissioning group (CCG) level for
those at risk of developing diabetes. The National Collaborating Centre for Indicator Development
(NCCID) works on behalf of the NICE to develop and evaluate quality measures of primary care.
Within primary care they have also been used to incentivise certain aspects of care through the Qual-
ity and Outcomes Framework (QOF).10
Evaluation has been part of the NCCID protocol since 2009 and is a recommended step by
the National Committee for Quality Assurance.11 Piloting measures can help identify any concerns
prior to use in assessment frameworks, thus giving time to adapt indicator wording or measurement
protocols to address issues such as tunnel vision, gaming, misinterpretation, and measure fixation.12
Quality measures
The desirable attributes of quality measures are validity, reliability, and acceptability to those being
assessed and those making the assessment, as well as feasibility, and cost-effectiveness11,13–
17 (Box 1).
Measures can be developed to evaluate structure (features of an organisation), process (related
activities), and outcome (change in health status),11,13 as appropriate.
Aims and objectives
The aim of this unique work is to develop and evaluate a set of quality measures for the identifica-
tion and management of people with NDH that are suitable for use in England at the general prac-
tice and CCG levels, as well as research questions that are relevant to clinical practice. The findings
from the focus groups will provide clinicians with insight into patients’ perspectives on and experien-
ces of communication and management of NDH. The specific objectives are:
1. to develop a comprehensive set of quality measures based on relevant NICE guidance and the
evidence of reviews underpinning NHS England’s Diabetes Prevention Programme;
2. to undertake preliminary evaluation of the validity and feasibility of these measures through
the use of a RAND consensus methodology;
3. to explore patients’ experiences of being identified with NDH and views on quality outcome
measures;
4. to develop and test data extraction specifications to support these measures at general practi-
ces including IT system compatibility; and
5. to evaluate the resulting measures in a 6-month pilot.
Method
Relevant NICE guidelines will be identified and used to underpin measure development alongside
evidence reviews supporting the development of the Diabetes Prevention
Programme.18,19 Recommendations from these will be developed into quality measure statements
initially with an ’IF, THEN, BECAUSE’ approach to ensure clarity in terms of population of interest;
the care activity to be undertaken; the circumstances under which this activity should be performed,
for example duration; and the rationale (Box 2).19
A comprehensive set of quality measures will be developed to address the multifaceted nature of
quality and the different organisational structures involved in the provision of this care, incorporating
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statements about structure, process, or outcomes to generate review criteria and standards that
help measure quality.20 Quality assessment can include processes (activities undertaken by the pro-
vider), outcomes (health or events following care), and risk adjustment (factors outside of the health
system [patient demographics, illnesses, treatment, and organisation]).21
RAND consensus methodology
The RAND appropriateness method uses a group judgment process to systematically and quantita-
tively incorporate expert opinion with scientific evidence, whereby panellists rate, discuss, and re-
rate quality measures.20 Benefits include the opportunity to discuss issues and maintain all potential
information, as no indicators are dropped between meetings, as well as the use of scientific litera-
ture. The RAND panel will be a convenience sample of GPs. Recruitment to the RAND panels will be
open to GPs from diverse backgrounds; for example, those with recent qualifications versus long-
standing registered GPs, salaried versus partnered GPs. However, panels can be small, patients are
rarely involved, and there is potential for dominant personalities to carry more influence.20
In a systematic review by Kotter et al, a consensus method was used in all 35 included studies, 15
of which used a modified RAND method to limit stakeholder influence and incorporate expert
opinion.22 The use of RAND in UK quality measurement has been outlined in research for conditions
such as angina and non-insulin dependent diabetes in general practice settings.23
The research panels will be undertaken with GPs and CCG commissioners which could result in
missing out patient experiences, but there is a risk in combining patient and professional views as
patients may be dominated by professionals.24
The clarity, validity, and feasibility of identified measures will be evaluated using a modified
RAND consensus methodology with groups of GPs and CCG level commissioners within Hereford-
shire CCG. A modified RAND methodology offers a unique systematic approach to synthesising the
evidence base underpinning the quality measures, using existing literature as well as professional
opinions.25 It has been widely used to develop quality measures in the UK and internationally.26
Each RAND panel will consist of two rounds of quality measure ranking (Figure 1).
Box 1. Desirable attributes of quality measures
Attribute Definition Importance
Content and
construct
validity
. The ability of the measure to accurately
capture the quality of care being
delivered
. The measure being able to cover
important aspects of care that contrib-
ute to perceptions of care quality
. The extent to which performance on a
measure correlates (positively or nega-
tively) with other aspects of care that
theories suggest it should correlate with
. To ensure that the quality measures
reflect the aspects of care interest to
members of the public, providers, and/
or regulators
Reliability . The accuracy with which a measure can
produce similar results under different
conditions (including people applying
the measure, and the situation in which
it is applied)
. To ensure that differences in perfor-
mance between providers and over
time are a true reflection of differences
in care
Feasibility . The ability to accurately measure the
quality indicator with ease and
efficiency
. To ensure that the information required
in order to calculate achievement
against the quality measure can be col-
lected easily and efficiently. If measures
require too much time, money or effort
then they may not be suitable for use
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Explore patient views
Qualitative research with patients lends itself to the enhancement of the validity and clarity of meas-
ures, not only for providers but also patients who face the consequences of being identified with the
condition and of being part of the healthcare system.
There is a diverse range of behaviour change theories that can help develop an understanding of
constructs regarding people’s behaviour.27 The COM-B model provides three factors — capability,
opportunity and motivation — to develop behavioural targets as a basis for intervention
design.28 The model encompasses a variety of psychosocial factors that can determine initiation and
maintenance of behavioural change.29 The model has been applied successfully in a number of con-
texts to understand behaviour change.28 By investigating patient views and behaviours in relation to
health management, researchers can identify potential barriers to or facilitators for changing behav-
iour once an identification of chronic disease risk has been made.
Although patient involvement in measure development has been carried out, there is a limited
number of works in this field, especially regarding details of involvement and representativeness.22
Patient views will be explored through a minimum of four focus groups, each consisting of 8–10
participants. Braun and Clarke suggest 3–6 focus groups can provide sufficient data for a medium
sized project.28 Data collection will be an iterative process where focus group recordings will be
transcribed and analysed to monitor data saturation and provide additional topics for subsequent
focus groups.30 Incorporating patient views will further strengthen understanding of quality measure
suitability. Furthermore, the use of the COM-B model of behaviour change to guide data collection,
analysis, and interpretation will provide findings that can be understood from different healthcare
perspectives, for example, for health interventions considering patient views on preventative care.29
Patients will be identified through direct recruitment from GP practices or through local support
networks as eligible for the focus groups if they:
. have been recorded as having NDH or their latest HbA1c was between 42–47 mmol/mol in
the last 6 months (Table 1); and
. are aged 18 years
The practice will be asked to send patients information sheets about the study and an invitation
to participate. No personal information will leave the practice/CCG. Patients will be contacted if
they are at risk and inclusion will not be limited to patients taking part in the diabetes prevention
programme.
The focus group will begin with an initial discussion of people’s experiences of diabetes preven-
tion care and then each potential measure will be presented to the group with the reason for its
development.
The topic guide will be used to gather data on participant’s views and experiences, and is struc-
tured based on the three integral components of the COM-B model — namely, capability
(both psychological and physical), motivation, and opportunity (physical and
environmental)29 (Box 3).
Participants’ experience of risk assessment can parallel the experience of illness and associated
social implications.31 Participants will therefore be encouraged to make suggestions not only to
Box 2. Quality measurement statement
IF, THEN, BECAUSE
statement
IF a patient has been identified as having NDH (HbA1c 6.0–6.4%/42–47 mmol/mol)
THEN they should be offered a blood test at least once a year BECAUSE they may
develop type 2 diabetes
Quality measure
statement
The percentage of patients with NDH who have had an HbA1c or fasting plasma
glucose in the preceding 12 months
Denominator Patients with NDH
Numerator Patients identified with NDH for whom there is a record of either an HbA1c or
fasting plasma glucose being measured in the preceding 12 months
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improve clarity and acceptability of the potential measures for diabetes prevention, but also to shed
light on their experiences and perception of having an elevated blood sugar level and their capabil-
ity, motivation, and opportunities in relation to it. Analysis of participants’ comments will be an itera-
tive process and run concurrently through data collection.
Quality measure piloting and evaluation
A convenience sample of five GP practices will be recruited in NHS Herefordshire CCG to a maxi-
mum of 24 (whole health economy).
Practices which agree to take part will be expected to:
1. Work with the quality measure for the 6 months of the pilot.
2. Complete baseline and end of pilot computerised data extraction of quality measure
achievement;
 electronic data will be extracted for participating practices using EMIS web queries at the
beginning and end of the pilot period in order to assess how performance against the
measure changed over time. Demographic data will be extracted to explore potential dif-
ferences as a result of age, sex, and ethnicity.
3. Complete a workload diary for 1 month of the pilot;
 these consist of completing a spreadsheet that monitors how much time was spent on
each quality measure.
4. Complete an end of pilot interview.
The lead GP at each practice and any other staff, including diabetic nurses who were actively
involved in piloting, will be interviewed at the end of the pilot.
All interviews will be audiorecorded and transcribed verbatim. Data will be analysed
thematically.32
Cost-effectiveness analysis
For any QOF indicators developed from the agreed measures, their cost-effectiveness will be deter-
mined using a net (monetised) benefit approach.33 In summary, the method applies the following
calculation to an indicator:
Figure 1. RAND consensus methodology process for panellists.
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Net benefit = (monetised health benefit – delivery cost) – QOF payment.
QOF payments are an incentive paid to GP practices when certain quality thresholds relating to
the indicators are achieved.
The costs and benefits for each indicator are estimated through a rapid review of the available
economic evidence. Evidence of delivery costs and benefits, expressed as quality-adjusted life years
(QALYs), is sought. The opinions of those involved in delivering the indicators at pilot GP sites are
also sought.
The costs associated with an indicator include service delivery costs; for example, the costs of
additional GP or nurse consultations to monitor a patient’s health status over a period of time, the
initial cost of implementing the intervention, and, if relevant, secondary care service usage. Unit
costs will either be extracted from the literature review or derived from published sources such as
NHS Reference Costs.
The benefits refer to health benefits which might be gained by a patient as a result of the intro-
duction of the indicator. Effectiveness will be derived from the literature in the form of utility values,
which can be converted to QALYs. The monetised health benefit of the indicator refers to the value
of the health improvements associated with achieving the predicted benefits of the indicator. These
benefits are presented in terms of the changes in QALYs as a result of introducing the new indicator
compared to standard practice without the new indicator.
Sensitivity analysis is performed through simple scenario analysis rather than probabilistic sensitiv-
ity analysis.
Practical issues
The focus groups will be conducted with two members of the research team and all focus group
interviews will be analysed and verified among the team to limit research subjectivity or bias of one
researcher.34
Participants are free to withdraw from the research at any time without giving any reason. There
is no intervention, manipulation or deception taking place.
Discussion
Summary
The study undertakes the piloting of quality measure validity, credibility, and feasibility as part of the
diabetes prevention programme.
Strengths and limitations
The strengths of this study include: a practical design; patient evaluation, which is rarely carried out
and will contribute to a wider understanding of identification of NDH and consequences (if any) on
quality of life; a theoretical framework to inform data collection in the focus group; exploration of
patient experiences to provide insight into identification of NDH and measure appropriateness;
Table 1. Diagnostic threshold table HbA1c (fasting glucose)
Risk % mmol/mol
Normal <6.0 <42
Pre-diabetes/NDH 6.0–6.4 42–47
Diabetes 6.5 48
Exclusion:
. Patients will be excluded if their HbA1c is within the pre-diabetes/NDH range
(6.0–6.4) but they are known to have diabetes or impaired glucose tolerance as a
result of pregnancy.
. The resulting list will be reviewed by a GP in the practice to identify and remove
patients whom it would be inappropriate to contact, for example,. those at end
of life.
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and piloting, which will allow the evaluation of quality measures before they are implemented as
part of a longitudinal national project. Insight into patient experiences and perspectives on quality
measures will help care providers and health services to understand the effects of identification and
its consequences for patients’ lifestyle, engagement with care services, and overall wellbeing.
Nonetheless, there are challenges with recruiting and retaining participants across a multi-stage
piloting process. GP practices within the overall Herefordshire health economy will be approached
and potentially recruited to participate in the study. The identification by the GP of patients meeting
the inclusion criteria and the inviting of participants to take part in the research may be limited to
participants who are actively aware of their risk and not apprehensive about discussing it.
Managing practices to collect baseline and final measurements from patients may create poten-
tial difficulties. This will require a considerable amount of resources to meet the recruitment targets
and involve collaboration with NHS Herefordshire. Any issues with non-responsive patients will be
discussed with the practice manager.
The RAND methodology is also limited in its ability to incorporate patient views, but this study
aims to address this by carrying out a number of focus group sessions to gather data on patients’
experiences of being identified as having NDH and their views on quality measures. Although RAND
panels may be limited in group size and the piloting focus is restricted to one geographical area
(Hereford) that is not representative of England, the research will not only gauge expert opinion, but
will also incorporate patient views on these measures and any implications which identification of
pre-diabetes has for their emotional wellbeing.
Herefordshire CCG is a first wave implementation site of the diabetes prevention programme.
The population provides the opportunity to sample individuals from a lower rural socioeconomic sta-
tus. However, Herefordshire is a relatively homogenous area in terms of ethnicity and this could limit
generalisability of the focus groups. Focus groups should be replicated in more diverse areas.
The focus of the current pilot is not on outcome-driven quality measures in diabetes prevention
care, as they are not normally rewarded. The findings may suggest alternative measures need to be
implemented to support process and risk adjustment factors.
The pilot will contribute to the evidence base about quality measure piloting and implementation,
but also inform the Diabetes Prevention Programme about barriers and facilitators to the manage-
ment of care for people with NDH.
Funding
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Box 3. Questions and probes from the topic guide
Example of an opening question
What do you think good care is?
. How would you describe the quality of the care that you receive?
Example of a question regarding patient’s emotions
What does it feel like to have pre-diabetes as a label in your records?
. Were you expecting this? Why?
Discussion on quality indicators
What do you think about repeating blood tests?
. What do you feel about this?
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